THE COST-EFFECTIVENESS OF ATIDARSAGENE AUTOTEMCEL (ARSA-CEL) FOR THE TREATMENT OF METACHROMATIC LEUKODYSTROPHY (MLD) IN THE US

被引：0
|
作者：
Pang, F. [1 ]
Dean, R. [2 ]
Jensen, I. S. [2 ]
Bean, K. [1 ]
Fields, C. [3 ]
Miller, B. [2 ]
机构：
[1] Orchard Therapeut Ltd, London, England
[2] Precis Hlth Econ Outcomes Res, Boston, MA USA
[3] Orchard Therapeut Ltd, Boston, MA USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE393
引用
收藏
页码：S126 / S126
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF ATIDARSAGENE AUTOTEMCEL (ARSA-CEL) GENE THERAPY FOR TREATING METACHROMATIC LEUKODYSTROPHY (MLD) IN IRELAND, BELGIUM, AND THE NETHERLANDS AS A PART OF THE BENELUXA INITIATIVE
    Olaye, A.
    Bean, K.
    Velikanova, R.
    Wolters, S.
    Miller, B.
    Jensen, I
    Pang, F.
    VALUE IN HEALTH, 2024, 27 (12)
  • [2] THE COST-EFFECTIVENESS OF ATIDARSAGENE AUTOTEMCEL FOR THE TREATMENT OF METACHROMATIC LEUKODYSTROPHY (MLD) IN FRANCE
    Pang, F.
    Dean, R.
    Jensen, I
    Tehard, B.
    Roze, S.
    Olaye, A.
    Bean, K.
    Miller, B.
    VALUE IN HEALTH, 2022, 25 (07) : S339 - S339
  • [3] The cost-effectiveness of atidarsagene autotemcel for the treatment of metachromatic leukodystrophy in France
    Pang, Francis
    Dean, Rebecca
    Jensen, Ivar
    Tehard, Bertrand
    Roze, Stephane
    Olaye, Andrew
    Bean, Karen
    Miller, Beck
    MOLECULAR GENETICS AND METABOLISM, 2022, 135 (02) : S93 - S93
  • [4] The cost-effectiveness of OTL-200 for the treatment of metachromatic leukodystrophy (MLD) in the US
    Pang, Francis
    Dean, Rebecca
    Jensen, Ivar
    Bean, Karen
    Fields, Christopher
    Miller, Beckley
    MOLECULAR GENETICS AND METABOLISM, 2023, 138 (02) : 100 - 100
  • [5] THE COST-EFFECTIVENESS OF OTL-200 FOR THE TREATMENT OF METACHROMATIC LEUKODYSTROPHY (MLD)
    Pang, F.
    Dean, R.
    Jensen, I
    Olaye, A.
    Miller, B.
    VALUE IN HEALTH, 2021, 24 : S203 - S203
  • [6] LENTIVIRAL HAEMATOPOIETIC STEM CELL GENE THERAPY (ATIDARSAGENE AUTOTEMCEL) FOR LATE JUVENILE METACHROMATIC LEUKODYSTROPHY (MLD)
    Gallo, Vera
    Calbi, Valeria
    De Mattia, Fabiola
    Zambon, Alberto
    Recupero, Salvatore
    Fratini, Elena
    Ciotti, Francesca
    Fraschini, Maddalena
    Sangalli, Mara
    Sarzana, Marina
    Clerici, Alessandra
    Morena, Francesco
    Martino, Sabata
    Brooks, Jean
    Richardson, Alan
    Campbell, Laura
    Bernardo, Maria Ester
    Aiuti, Alessandro
    Fumagalli, Francesca
    BONE MARROW TRANSPLANTATION, 2024, 59 : 95 - 96
  • [7] THE COST-EFFECTIVENESS OF NEWBORN SCREENING FOR METACHROMATIC LEUKODYSTROPHY (MLD) IN THE UK
    Bean, K.
    Jones, S.
    Chakrapani, A.
    Vijay, S.
    Wu, T. H. Y.
    Church, H. J.
    Pang, F.
    VALUE IN HEALTH, 2022, 25 (01) : S79 - S79
  • [8] Lentiviral hematopoietic stem cell gene therapy (atidarsagene autotemcel) for late juvenile metachromatic leukodystrophy (MLD)
    Gallo, Vera
    Calbi, Valeria
    De Mattia, Fabiola
    Zambon, Alberto Andrea
    Recupero, Salvatore
    Fratini, Elena Sophia
    Ciotti, Francesca
    Fraschini, Maddalena
    Sangalli, Mara
    Sarzana, Marina
    Clerici, Alessandra
    Morena, Francesco
    Martino, Sabata
    Brooks, Jean
    Richardson, Alan
    Campbell, Laura
    Aiuti, Alessandro
    Fumagalli, Francesca
    MOLECULAR GENETICS AND METABOLISM, 2024, 141 (02)
  • [9] Exploring the Cost-Effectiveness of Newborn Screening for Metachromatic Leukodystrophy (MLD) in the UK
    Bean, Karen
    Jones, Simon A.
    Chakrapani, Anupam
    Vijay, Suresh
    Wu, Teresa
    Church, Heather
    Chanson, Charlotte
    Olaye, Andrew
    Miller, Beckley
    Jensen, Ivar
    Pang, Francis
    INTERNATIONAL JOURNAL OF NEONATAL SCREENING, 2024, 10 (03)
  • [10] A systematic review of clinical effectiveness and safety for historical and current treatment options for metachromatic leukodystrophy in children, including atidarsagene autotemcel
    Armstrong, Nigel
    Olaye, Andrew
    Noake, Caro
    Pang, Francis
    ORPHANET JOURNAL OF RARE DISEASES, 2023, 18 (01)
12345